Aureka has established multiple co-discovery partnerships with leading pharma and biotech companies, with demonstrated success in designing novel antibody therapeutics for difficult targets and mechanisms while cutting time and cost.

Our platform excels in high-value yet challenging applications like antibody design for undruggable targets (e.g. GPCRs, conformational epitopes, promiscuous receptors), innovative antibodies with unique properties (e.g. dual targeting, pH-sensitivity, epitope selectivity, BBB-crossing), and novel modalities (e.g. nanobodies, bispecific antibodies, T-cell engagers, TCR mimics, biparatopic ADCs, protein degraders).

Download our application notes.

Aureka is also keen to collaborate with ecosystem partners to enhance our platform's value across various protein design applications. We are proud members of the NVIDIA Inception and MedTech/Biotools innovator accelerator programs.

Contact us today to learn more about how we can work together to make a difference in human health.